Psychostimulant Use Among Myeloproloferative Neoplasm Patients

Background: Fatigue remains one of the most severe and disabling symptoms experienced by patients with myeloproliferative neoplasms (MPNs) resulting in impaired social, role, and physician functioning and reduced quality of life (Cancer 2007). Current NCCN Clinical Practice Guidelines in Oncology recommend consideration of use of psychostimulants (PSs) if other causes of fatigue have been ruled out. In this analysis, we evaluate the role of pharmacologic PSs in this population utilizing data from a previously conducted a survey regarding fatigue in MPN patients (Cancer 2016).